These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20518326)

  • 1. [Analysis and evaluation on quality of live attenuated measles vaccine from market surveillance sampling].
    Fang HH; Wang XX; Yi M
    Zhongguo Yi Miao He Mian Yi; 2009 Dec; 15(6):511-5. PubMed ID: 20518326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy evaluation of measles vaccine in fields].
    Liu M
    Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Oct; 12(5):292-4. PubMed ID: 1782660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and serological studies with a live further attenuated measles vaccine (Moraten) in Chile].
    Ristori C; Boccardo H; Borgoño JM; Greiber R; Heras E; Carrillo B; Solari G; Concha F
    Rev Med Chil; 1970 Jan; 98(1):42-5. PubMed ID: 4157374
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines.
    Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R
    Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety and immunogenicity of measles attenuated live vaccine prepared by master seed lot vaccine of Shanghai-191 strain].
    Zhang SJ; Xiao QY; Li FJ
    Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):423-5. PubMed ID: 20084967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimizing cultural conditions of measles vaccine working seed lot with orthogonal experiments].
    Chen T; Chen P; Jia W; Liu Y; Jiang R; Peng W; Shi D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):421-3. PubMed ID: 12910678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
    Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
    Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein.
    Wang Y; Liu R; Lu M; Yang Y; Zhou D; Hao X; Zhou D; Wang B; Li J; Huang YW; Zhao Z
    Virology; 2018 May; 518():210-220. PubMed ID: 29525671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Measurement of the in vitro immune response of live attenuated measles virus vaccine and antibody levels in 0 to 10-year-old children].
    Unalan H; Ustaçelebi S
    Mikrobiyol Bul; 1985 Oct; 19(4):218-28. PubMed ID: 3831724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.
    Rennick LJ; de Vries RD; Carsillo TJ; Lemon K; van Amerongen G; Ludlow M; Nguyen DT; Yüksel S; Verburgh RJ; Haddock P; McQuaid S; Duprex WP; de Swart RL
    J Virol; 2015 Feb; 89(4):2192-200. PubMed ID: 25473055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE; Peetermans J
    Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and evaluation of the TD97 measles virus vaccine.
    Suzuki K; Morita M; Katoh M; Kidokoro M; Saika S; Yoshizawa S; Hashizume S; Horiuchi K; Okabe N; Shinozaki T
    J Med Virol; 1990 Nov; 32(3):194-201. PubMed ID: 2280260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current problems in measles. II. Measles vaccines--recent progress].
    Ciufecu E
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(3):259-78. PubMed ID: 6438773
    [No Abstract]   [Full Text] [Related]  

  • 15. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
    Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
    Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the cold chain technology in South-East, Nigeria using Immunogenicity study on the measles vaccines.
    Oli AN; Agu RU; Ihekwereme CP; Esimone CO
    Pan Afr Med J; 2017; 27(Suppl 3):28. PubMed ID: 29296163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
    Brandler S; Tangy F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of immunity against measles in persons immunized with Edmonston-Zagreb vaccine.
    abu Eldan J; Borćić B; Smerdel S
    Acta Med Croatica; 1991; 45(4-5):297-304. PubMed ID: 1726513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of potency testing of poliomyelitis and measles vaccines as an integral part of cold chain surveillance.
    Saraswathy TS; Sinniah M; Lee WS; Lee PC
    Southeast Asian J Trop Med Public Health; 1993 Jun; 24(2):265-8. PubMed ID: 8266228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of measles inoculations in the Hungarian People's Republic].
    Erdös L
    Tr Inst Im Pastera; 1979; 53():19-25. PubMed ID: 262709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.